Novartis plans to spin off its generic medicines division, Sandoz, and has proposed offering shareholders one Sandoz share for every five Novartis shares. The Swiss drugmaker’s board unanimously endorsed the spin-off and invited shareholders to an extraordinary general meeting on Sept. 15. If approved, the distribution will be executed through a dividend-in-kind of Sandoz shares to Novartis shareholders. Sandoz accounted for approximately 10% of the company’s core operating profit in 2022. The decision to spin off Sandoz follows a strategic review by Novartis CEO Vas Narasimhan in response to pricing pressures in the U.S. generic drug sector.
Novartis on Friday proposed to offer shareholders one Sandoz share for every five Novartis shares as it said it planned to spin off the generic medicines division on or around Oct. 4.
The Swiss drugmaker invited shareholders to an extraordinary general meeting on Sept. 15 after its board of directors unanimously endorsed and recommended the proposed spin-off, the company said in a statement.
“If Novartis shareholders approve the proposed special distribution at the EGM, the Spin-off will be implemented through the distribution of a dividend-in-kind of Sandoz shares to Novartis shareholders, and of Sandoz ADRs (American Depositary Receipts) to Novartis ADR holders,” it said.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Sandoz, which accounted for about 10% of group core operating profit of $16.7 billion in 2022, was put under a strategic review by Novartis CEO Vas Narasimhan in 2021 following mounting pricing pressures in the U.S. off-patent drug sector.
Novartis announced plans for the spin-off in August 2022.
Source: CNBC
